1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470 "Cancer")
Fax: (412) 641-1675
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have full text access to this OnlineOpen article
Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy†
A single institutional experience with 359 cases
Article first published online: 3 FEB 2010
DOI: 10.1002/cncr.24876
Copyright © 2010 American Cancer Society
Additional Information
How to Cite
Bhargava, R., Beriwal, S., Dabbs, D. J., Ozbek, U., Soran, A., Johnson, R. R., Brufsky, A. M., Lembersky, B. C. and Ahrendt, G. M. (2010), Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy. Cancer, 116: 1431–1439. doi: 10.1002/cncr.24876
- †
We thank Louise Mazur and Karen Baurle for clerical assistance.
Publication History
- Issue published online: 3 MAR 2010
- Article first published online: 3 FEB 2010
- Manuscript Accepted: 10 JUL 2009
- Manuscript Revised: 17 JUN 2009
- Manuscript Received: 1 APR 2009
Corrected by:
Vol. 117, Issue 10, 2238, Article first published online: 10 NOV 2010
REFERENCES
- 1, , . Preoperative (neoadjuvant) systemic treatment of breast cancer. Breast. 2005; 14: 576-581.
- 2, , , et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol. 2008; 26: 814-819.
- 3
- 4, . Preoperative therapy in breast cancer: lessons from the treatment of locally advanced disease. Oncologist. 2002; 7: 239-245.
- 5, , . Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005; 97: 188-194.
- 6, , . Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol. 2007; 608: 1-22.
- 7, , . Primary docetaxel chemotherapy in patients with breast cancer: impact on response and survival. Breast Cancer Res Treat. 2005; 90: 169-185.
- 8, . Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania. Cancer. 2004; 100: 2512-2532.Direct Link:
- 9, , , et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002; 20: 1456-1466.
- 10, , , et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005; 11: 5678-5685.
- 11, , , et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007; 13: 2329-2334.
- 12, , , et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006; 295: 2492-2502.
- 13, , , et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004; 10: 5367-5374.
- 14, , , et al. Basal-like breast cancer defined by 5 biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008; 14: 1368-1376.
- 15, , , , . Histopathologic variables predict Oncotype DX recurrence score. Mod Pathol. 2008; 21: 1255-1261.
- 16, , , , . Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985; 109: 716-721.
- 17, , , et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology. 2006; 49: 22-34.Direct Link:
- 18, , , et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003; 12: 320-327.
- 19, , , et al. Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers. Int J Clin Exp Pathol. 2009; 2: 444-455.
- 20, , , et al. Molecular portraits of human breast tumours. Nature. 2000; 406: 747-752.
- 21, , , et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98: 10869-10874.
- 22, , , et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003; 100: 8418-8423.
- 23. Molecular classification of breast tumors: toward improved diagnostics and treatments. Methods Mol Biol. 2007; 360: 91-114.
- 24, , , et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009; 27: 1160-1167.
- 25, . Luminal B breast tumors are not HER2 positive. Breast Cancer Res. 2008; 10: 404. Author reply 405.
- 26, , , et al. Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas). Mod Pathol. 2007; 20: 1200-1207.
- 27, , , et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat. 2008; 111: 27-44.